X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA FULFORD INDIA ELDER PHARMA/
FULFORD INDIA
 
P/E (TTM) x -0.2 398.8 - View Chart
P/BV x 0.1 6.2 1.6% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ELDER PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
FULFORD INDIA
Mar-14
ELDER PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs380942 40.3%   
Low Rs188450 41.8%   
Sales per share (Unadj.) Rs491.2691.4 71.0%  
Earnings per share (Unadj.) Rs-3.211.5 -27.8%  
Cash flow per share (Unadj.) Rs14.415.4 93.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs376.5380.0 99.1%  
Shares outstanding (eoy) m20.543.90 526.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.0 57.4%   
Avg P/E ratio x-89.360.7 -147.0%  
P/CF ratio (eoy) x19.745.3 43.5%  
Price / Book Value ratio x0.81.8 41.2%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m5,8332,714 214.9%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m2,179505 431.5%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m10,0892,696 374.2%  
Other income Rs m257125 204.6%   
Total revenues Rs m10,3462,822 366.6%   
Gross profit Rs m-792-46 1,706.7%  
Depreciation Rs m36115 2,377.0%   
Interest Rs m2,75610 29,013.7%   
Profit before tax Rs m-3,65354 -6,727.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m12510 1,303.6%   
Profit after tax Rs m-6545 -146.2%  
Gross profit margin %-7.8-1.7 456.1%  
Effective tax rate %-3.417.7 -19.4%   
Net profit margin %-0.61.7 -39.1%  
BALANCE SHEET DATA
Current assets Rs m9,2401,738 531.6%   
Current liabilities Rs m9,998545 1,835.4%   
Net working cap to sales %-7.544.3 -17.0%  
Current ratio x0.93.2 29.0%  
Inventory Days Days4648 95.5%  
Debtors Days Days604 1,392.4%  
Net fixed assets Rs m10,12412 85,073.1%   
Share capital Rs m20639 527.4%   
"Free" reserves Rs m5,5821,443 386.9%   
Net worth Rs m7,7341,482 521.8%   
Long term debt Rs m4,8890-   
Total assets Rs m22,8822,077 1,101.8%  
Interest coverage x-0.36.7 -4.8%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.3 34.0%   
Return on assets %11.82.6 450.6%  
Return on equity %-0.83.0 -28.0%  
Return on capital %22.34.3 518.2%  
Exports to sales %3.00-   
Imports to sales %0.424.5 1.7%   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43659 6.5%   
Fx inflow Rs m30717 1,782.6%   
Fx outflow Rs m125673 18.6%   
Net fx Rs m181-656 -27.6%   
CASH FLOW
From Operations Rs m11,75490 13,060.1%  
From Investments Rs m-561105 -535.9%  
From Financial Activity Rs m-6,762-14 47,956.0%  
Net Cashflow Rs m4,432181 2,455.2%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 3.8 197.4%  
FIIs % 16.8 0.1 16,800.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.2 170.3%  
Shareholders   16,479 4,783 344.5%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SUN PHARMA  IPCA LABS  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - ABBOTT INDIA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS